Arvinas (ARVN) Insider Everett Cunningham Buys 15,527 Shares
Everett Cunningham purchased 22,714 shares of Arvinas, Inc. on June 24.
Reviewed by automated data checks against the source filing. How we make and check alerts
Everett Cunningham bought 15,527 shares of Arvinas, Inc. ($ARVN) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ARVN is up 1.9% after 1 week, down 0.2% after 1 month and down 13.4% to date (from the $8.05 close on Jun 24, 2026).
ARVN
Arvinas, Inc.
Key Points
- Everett Cunningham bought 22,714 shares of Arvinas, Inc. on June 24, 2026, with shares trading near $8.03 on Saturday.
- Arvinas, Inc. has a market cap of about $518 million, with a 52-week range between $6.06 and $14.51.
- Analysts from Stephens & Co., Barclays, and Citigroup maintain a buy rating, with price targets up to $24.
Get $ARVN trade alerts by text
We text you when insiders, Congress or big funds trade $ARVN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Arvinas, Inc. alert may contain errors. Disclosures
On June 24, 2026, Everett Cunningham purchased 22,714 shares of Arvinas, Inc. on the NasdaqGS under the ticker ARVN. This insider buying activity comes as shares traded near $8.03 on Saturday.
Insider Buying and Selling at Arvinas, Inc.
In addition to Everett Cunningham, several other insiders, including Linda Bain, Edward Moore Jr., Laurie Smaldone Alsup, Briggs Morrison, and Leslie Norwalk, also purchased shares of Arvinas, Inc. on June 24. Each transaction involved buying 15,527 or 22,714 shares, reflecting a coordinated buying effort.
Arvinas, Inc. Stock Down 3.5%
Shares of NasdaqGS:ARVN traded near $8.03 on Saturday. Arvinas, Inc. has a market cap of $518.1 million. The company is not currently profitable, so it has no meaningful P/E ratio. The stock has ranged from a 52-week low of $6.06 to a high of $14.51. Its 50-day moving average is $9.08, and the 200-day moving average is $10.67. Arvinas has a strong liquidity position with a current ratio of 5.44 and a quick ratio of 5.36, alongside a debt-to-equity ratio of 2.17.
Analysts Set New Price Targets
On June 3, 2026, Stephens & Co. reiterated a buy rating for Arvinas, Inc. with a price target of $18. Barclays and BTIG maintained their buy ratings on May 13, with targets of $20 and $18, respectively. Citigroup also maintained its buy rating, setting the highest target at $24 on May 4. The consensus among 15 analysts is a buy rating, with a mean target price of $14.80.
About Arvinas, Inc.
Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut. Founded in 2013, the company focuses on developing therapies to degrade disease-causing proteins using its PROTAC technology. Its pipeline includes treatments for various diseases, such as neurodegenerative disorders and cancers. Led by CEO Dr. Randy Teel, Arvinas collaborates with major pharmaceutical companies like Pfizer and Genentech.
Bottom Line
Insider buying by Everett Cunningham and others signals confidence in Arvinas, Inc. despite its current unprofitability. Investors often track such insider activities as they may hint at the company's potential. Keep in mind, however, that these transactions are backward-looking and may not reflect current positions.
Related Filing Alerts
Source: Everett Cunningham's Form 4 filing on $ARVN (Jun 24, 2026). Find the original filing: ARVN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts